Genmab — December 2024
-
"In the event of febrile neutropenia,
patients should be evaluated for infection and managed with antibiotics, fluids and other supportive care,
according to local guidelines." "Of the 105
patients who had neutropenia/neutrophil count decreased events, 61% received G-CSF to treat the
events" https://www.ema.europa.eu/en/documents/product-information/tepkinly-epar-product-information_en.pdf -
by chance this article today, shows- There are limited data on the use of G-CSF in anti-CD20 BsAbs. In a study of mosunetuzumab for R/R B-NHL, a total of 60/218 (27.5%) patients experienced a neutropenic event, and 41/60 patients (68.3%) received G-CSF, with a positive response in 39/41 patients (95.1%). A phase I trial of glofitamab noted that G-CSF was administered in 37 patients (21.6%), while a dose-expansion phase I/II study of epcoritamab noted that only 10.1% of patients required G-CSF
-
-
-
Onsdag d. 11. december......
Genmab vil holde sin Forsknings- og Udviklingsopdatering og gennemgang af de data, der præsenteres i forbindelse med for American Society of Hematology, ASH’s, årlige møde. Begivenheden, der løber af stablen onsdag klokken 17, har ikke noget med det generelle program at gøre. -
Investigational Epcoritamab (DuoBody
CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis https://ir.genmab.com/news-releases/news-release-details/investigational-epcoritamab-duobodyr-cd3xcd20-monotherapy -
Bispecific Antibody Elicits High Responses Among Patients With Heavily Pretreated CLL - Epcoritamab - https://ashpublications.org/ashclinicalnews/news/8275/Bispecific-Antibody-Elicits-High-Responses-Among?searchresult=1&utm_source=twitter&utm_medium=organic_social&utm_term=ashclinicalnews&utm_content=c49e3a3b-b64c-4357-a1a7-f2c933057b8c&utm_campaign=
-
Exploring New Frontiers in Chronic Lymphocytic Leukemia (CLL) Treatment: A Q&A With City of Hope’s Dr. Danilov https://www.linkedin.com/pulse/exploring-new-frontiers-chronic-lymphocytic-leukemia-cll-n9u1c/?trackingId=/rRSFPDq0eXIPCTAGmg6pg%3D%3D
-
slides - #ASH24 | Alexey Danilov: epcoritamab monotherapy in patients with R/R #chroniclymphocyticleukemia: results from #CLL expansion and optimization cohorts of Epcore CLL-1 https://x.com/EmatoInfo/status/1865795985567354959
-
‘Double-Barreled’ Drug Shows Early Promise for Blood Cancer https://www.cityofhope.org/double-barreled-drug-shows-early-promise-for-blood-cancer
-
DARZALEX FASPRO
(daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma https://www.jnj.com/media-center/press-releases/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-shows-51-percent-reduction-in-risk-of-progression-to-active-multiple-myeloma-for-patients-with-high-risk-smoldering-multiple-myeloma -
TECVAYLI
(teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma https://innovativemedicine.jnj.com/our-innovation/focus-areas/oncology/tecvayli-teclistamab-cqyv-demonstrates-potential-as-frontline-combination-therapy-for-patients-with-newly-diagnosed-multiple-myeloma -
E L..Thank you from the bottom of my heart for your daily tireless distribution of big and small news from Genmab and the pipeline.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind